-+ 0.00%
-+ 0.00%
-+ 0.00%

iBio Presents New Preclinical Data Across Obesity and Cardiometabolic Portfolio At PEGS Europe 2026 And Amylin-Based Therapeutics Summit

Benzinga·11/16/2026 21:39:37
Listen to the news

ObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28.

Amylin program data demonstrating reduced food intake in rats to be presented at PEGS Europe and the Amylin-Based Therapeutics Summit

Together, the findings highlight the potential of iBio’s antibody discovery platform to generate highly specific candidates against distinct targets